Merck Cozaar Will Get Stroke Risk Reduction Claim – FDA’s Temple
Executive Summary
Merck Cozaar data from the LIFE study support a risk reduction claim for strokes rather than a broader new indication, FDA Office of Medical Policy Director Robert Temple, MD, said
You may also be interested in...
King & Spalding’s healthcare practice expands
King & Spalding announced the addition of two senior advisors to its healthcare practice July 24. Beverly Lorell, most recently VP and Chief Medical and Technology Officer at Guidant, will specialize in areas such as clinical trial design, recalls, and pre-marketing materials. Lorell served on FDA's Cardiovascular and Renal Drugs Advisory Committee (1"The Pink Sheet" Jan. 13, 2003, p. 18). Attorney Kay Scanlan, a former consultant for biotech, drug and medical device industries, will specialize in reimbursement. Scanlan previously served in the Office of General Counsel for CMS and as director-reimbursement strategy for Biogen Idec...
King & Spalding’s healthcare practice expands
King & Spalding announced the addition of two senior advisors to its healthcare practice July 24. Beverly Lorell, most recently VP and Chief Medical and Technology Officer at Guidant, will specialize in areas such as clinical trial design, recalls, and pre-marketing materials. Lorell served on FDA's Cardiovascular and Renal Drugs Advisory Committee (1"The Pink Sheet" Jan. 13, 2003, p. 18). Attorney Kay Scanlan, a former consultant for biotech, drug and medical device industries, will specialize in reimbursement. Scanlan previously served in the Office of General Counsel for CMS and as director-reimbursement strategy for Biogen Idec...
Meta-Analysis In Lancet Projects End of Beta-Blockers For Hypertension
Beta-blockers should not remain the first-line therapy for high blood pressure, researchers of a study published in the Oct. 18 Lancet said